This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights Microsoft, Novo Nordisk, United Parcel Service, Booking and Elevance Health
by Zacks Equity Research
Microsoft, Novo Nordisk, United Parcel Service, Booking and Elevance Health are included in this Analyst Blog.
Will Elevance (ELV) Beat Q1 Earnings on Carelon Strength?
by Zacks Equity Research
The first-quarter results of Elevance (ELV) are likely to reflect higher product revenues and Commercial Individual membership growth.
Top Analyst Reports for Microsoft, Novo Nordisk & United Parcel
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and United Parcel Service, Inc. (UPS).
Medpace (MEDP) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Medpace (MEDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elevance Health (ELV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Elevance Health (ELV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elevance Health (ELV) Brand Inks Deal to Better Serve Georgia
by Zacks Equity Research
Elevance Health's (ELV) brand, Anthem Blue Cross and Blue Shield, collaborates to make the benefits of Piedmont's healthcare network available to its members across specific Georgia regions.
ELV vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ELV vs. GDRX: Which Stock Is the Better Value Option?
Why Elevance Health (ELV) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Elevance Health (ELV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Wall Street Set to See a Broad-Based Rally in Q2: 5 Picks
by Nalak Das
It will be prudent to invest in non-technology stocks with a favorable Zacks Rank to gain in the near future. Five such stocks are: WELL, GIS, ELV, RCL, RYAAY.
Health Insurance Stocks Drop: Insights Into the Late Monday Fall
by Kaibalya Pravo Dey
Higher costs and lower hikes in rates can lead to lower profit growth, which concerns investors.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Elevance Health (ELV) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Elevance Health (ELV) closed at $513.85, marking a -0.16% move from the previous day.
ELV or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. GDRX: Which Stock Is the Better Value Option?
Humana (HUM), DUOS Unveil Program to Improve Veterans' Health
by Zacks Equity Research
Humana (HUM) collaborates with DUOS to develop a program that aims to provide personalized care and assure the well-being of Louisiana's Veteran community, who have a HUM MA plan and suffer from chronic conditions.
Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sera Prognostics (SERA) delivered earnings and revenue surprises of 0% and 56.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the fourth quarter of fiscal 2024.
3 Stocks to Buy for Decreased Volatility
by Derek Lewis
For those seeking a more conservative approach, low-beta stocks are common targets. Interestingly enough, analysts have recently become bullish on these three.
HealthEquity (HQY) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 12.50% and 1.48%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?
Cencora (COR) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
Why Elevance (ELV) is a Smart Addition to Your Portfolio Now
by Zacks Equity Research
Elevance's (ELV) top line is poised to gain from rising product revenues, administrative fees and other revenues.
Elevance Health (ELV) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
The latest trading day saw Elevance Health (ELV) settling at $510.57, representing a +0.21% change from its previous close.
Zacks Industry Outlook Highlights Elevance Health, Cencora and ICON
by Zacks Equity Research
Elevance Health, Cencora and ICON are part of the Zacks Industry Outlook article.
3 Medical Services Stocks to Buy as Industry Trends Improve
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. ELV, COR and ICLR are set to gain the most. However, staffing shortages continue to disrupt the growth trend.
Brokers Suggest Investing in Elevance Health (ELV): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Elevance Health (ELV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?